Livingston G, Huntley J, Sommerlad A et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission [published correction appears in Lancet. 2023;402(10408):1132]. Lancet. 2020;396(10248):413–446.

Liang CS, Li DJ, Yang FC, Tseng PT, et al. Mortality rates in Alzheimer’s disease and non-alzheimer’s dementias: a systematic review and meta-analysis. Lancet Healthy Longev. 2021;2(8):e479–88.

Article  PubMed  Google Scholar 

GBD 2019 Collaborators. Global mortality from dementia: application of a new method and results from the global burden of Disease Study 2019. Alzheimers Dement (NY). 2021;7(1):e12200.

Article  Google Scholar 

Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2018;6(6):CD001190.

PubMed  Google Scholar 

Fink HA, Linskens EJ, MacDonald R, et al. Benefits and harms of prescription drugs and supplements for treatment of clinical Alzheimer-type dementia. Ann Intern Med. 2020;172(10):656–68.

Article  PubMed  Google Scholar 

Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006;(1):CD001747.

Birks JS, Chong LY, Grimley Evans J. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev. 2015;9(9):CD001191.

PubMed  Google Scholar 

Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med. 2012;366(10):893–903.

Article  CAS  PubMed  Google Scholar 

Cummings J, Osse AML, Cammann D, Powell J, Chen J. Anti-amyloid monoclonal antibodies for te treatment of Alzheimer’s Disease. BioDrugs. 2024;38(1):5–22.

Article  CAS  PubMed  Google Scholar 

Jönsson L, Wimo A, Handels R, et al. The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer’s disease: an EADC-EC viewpoint. Lancet Reg Health Eur. 2023;29:100657.

Article  PubMed  PubMed Central  Google Scholar 

Monacelli F, Rosa G. Cholinesterase inhibitors: cardioprotection in Alzheimer’s disease. J Alzheimers Dis. 2014;42(4):1071–7.

Article  CAS  PubMed  Google Scholar 

Karimi Tari P, Parsons CG, Collingridge GL, Rammes G. Memantine: updating a rare success story in pro-cognitive therapeutics. Neuropharmacology. 2024;244:109737.

Article  CAS  PubMed  Google Scholar 

Lopez OL, Becker JT, Wahed AS et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80(6):600-7. Erratum in: J Neurol Neurosurg Psychiatry. 2009;80(9):1056.

Gasper MC, Ott BR, Lapane KL. Is donepezil therapy associated with reduced mortality in nursing home residents with dementia? Am J Geriatr Pharmacother. 2005;3(1):1–7.

Article  CAS  PubMed  Google Scholar 

Truong C, Recto C, Lafont C, Canoui-Poitrine F, Belmin J, Lafuente-Lafuente C. Effect of cholinesterase inhibitors on mortality in patients with dementia: a systematic review of randomized and nonrandomized trials. Neurology. 2022. https://doi.org/10.1212/WNL.0000000000201161.

Article  PubMed  Google Scholar 

Lazzeroni LC, Halbauer JD, Ashford JW, et al. Memantine is associated with longer survival than donepezil in a Veterans affairs prescription database, 1997 to 2008. J Alzheimers Dis. 2013;36(4):791–8.

Article  CAS  PubMed  Google Scholar 

Stubendorff K, Larsson V, Ballard C, Minthon L, Aarsland D, Londos E. Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson’s disease with dementia: a prospective study. BMJ Open. 2014;4(7):e005158.

Article  PubMed  PubMed Central  Google Scholar 

McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019;3(3):CD003154.

PubMed  Google Scholar 

Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer’s disease: a systematic review and meta-analysis. PLoS ONE. 2015;10(4):e0123289.

Article  PubMed  PubMed Central  Google Scholar 

Kishi T, Matsunaga S, Oya K, Nomura I, Ikuta T, Iwata N. Memantine for Alzheimer’s disease: an updated systematic review and meta-analysis. J Alzheimers Dis. 2017;60(2):401–25.

Article  CAS  PubMed  Google Scholar 

Blanco-Silvente L, Castells X, Saez M, et al. Discontinuation, efficacy, and safety of cholinesterase inhibitors for Alzheimer’s disease: a meta-analysis and meta-regression of 43 randomized clinical trials enrolling 16,106 patients. Int J Neuropsychopharmacol. 2017;20(7):519–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT, Memantine, MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5(1):83–9.

Article  CAS  PubMed  Google Scholar 

Knorz AL, Quante A. Alzheimer’s Disease: efficacy of mono- and combination therapy. A systematic review. J Geriatr Psychiatry Neurol. 2022;35(4):475–86.

Article  PubMed  Google Scholar 

Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet. 2002;41(10):719–39.

Article  CAS  PubMed  Google Scholar 

Malone K, Hancox JC. QT interval prolongation and Torsades De Pointes with donepezil, rivastigmine and galantamine. Ther Adv Drug Saf. 2020;11:2042098620942416.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Howes LG. Cardiovascular effects of drugs used to treat Alzheimer’s disease. Drug Saf. 2014;37(6):391–5.

Article  CAS  PubMed  Google Scholar 

Zhang D, Shen X, Qi X. Resting heart rate and all-cause and cardiovascular mortality in the general population: a meta-analysis. CMAJ. 2016;188(3):E53–63.

Article  PubMed  Google Scholar 

Tabet N. Acetylcholinesterase inhibitors for Alzheimer’s disease: anti-inflammatories in acetylcholine clothing! Age Ageing. 2006;35(4):336–8.

Article  CAS  PubMed  Google Scholar 

Vaknine S, Soreq H. Central and peripheral anti-inflammatory effects of acetylcholinesterase inhibitors. Neuropharmacology. 2020;168:108020.

Article  CAS  PubMed  Google Scholar 

Pollak Y, Gilboa A, Ben-Menachem O, Ben-Hur T, Soreq H, Yirmiya R. Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production. Ann Neurol. 2005;57:741–5.

Article  CAS  PubMed  Google Scholar 

Reale M, Iarlori C, Gambi F, Lucci I, Salvatore M, Gambi D. Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1 beta and interleukin-6 release from lymphocytes of Alzheimer’s disease patients. Experimental Gerontol. 2005;40:165–71.

Article  CAS  Google Scholar 

Reale M, Iarlori C, Gambi F, et al. Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. J Neuroimmunol. 2004;148:162–71.

Article  CAS  PubMed  Google Scholar 

Mortazavian SM, Parsaee H, Mousavi SH, Tayarani-Najaran Z, Ghorbani A, Sadeghnia HR. Acetylcholinesterase inhibitors promote angiogenesis in chick chorioallantoic membrane and inhibit apoptosis of endothelial cells. Int J Alzheimers Dis 2013; 121068.

Andersen K, Lolk A, Martinussen T, Kragh-Sørensen P. Very mild to severe dementia and mortality: a 14-year follow-up the Odense study. Dement Geriatr Cogn Disord. 2010;29(1):61–7.

Article  PubMed  Google Scholar 

Villarejo A, Benito-León J, Trincado R, et al. Dementia-associated mortality at thirteen years in the NEDICES Cohort Study. J Alzheimers Dis. 2011;26(3):543–51.

Article  PubMed  Google Scholar 

Chih-Sung Liang CS, Li DJ, Yang FC, et al. Mortality rates in Alzheimer’s disease and non-alzheimer’s dementias: a systematic review and meta-analysis. Lancet Healthy Longev. 2021;2(8):e479–88.

Article  PubMed  Google Scholar 

Akaike A, Takada-Takatori Y, Kume T, Izumi Y. Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha4 and alpha7 receptors in neuroprotection. J Mol Neurosci. 2010;40(1–2):211–6.

Article  CAS  PubMed  Google Scholar 

Akasofu S, Kosasa T, Kimura M, Kubota A. Protective effect of donepezil in a primary culture of rat cortical neurons exposed to oxygen-glucose deprivation. Eur J Pharmacol. 2003;472(1–2):57–63.

Article  CAS  PubMed  Google Scholar 

Jia J, Wei C, Jia L, et al. Efficacy and safety of donepezil in Chinese patients with severe Alzheimer’s disease: a randomized controlled trial. J Alzheimers Dis. 2017;56(4):1495–504.

Article  CAS  PubMed  Google Scholar 

O’Regan J, Lanctôt KL, Mazereeuw G, Herrmann N. Cholinesterase inhibitor discontinuation in patients with Alzheimer’s disease: a meta-analysis of randomized controlled trials. J Clin Psychiatry. 2015;76(11):e1424–31.

Article  PubMed  Google Scholar 

Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2002;72(3):310–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Becker M, A